Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
26.02. | Arcus Biosciences stock rating upgraded to Buy at H.C. Wainwright | 23 | Investing.com | ||
25.02. | Arcus Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
25.02. | Arcus Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
19.02. | Arcus Biosciences stock target cut to $18 at H.C. Wainwright | 4 | Investing.com | ||
ARCUS BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
18.02. | Arcus Biosciences Shares Are Down Today: What's Going On? | 1 | Benzinga.com | ||
18.02. | Arcus Biosciences Prices 13.6 Mln Offering At $11.00/shr, Stock Slide In Pre-market | 1 | RTTNews | ||
18.02. | Arcus Biosciences stock dips after pricing $150M offering | 1 | Seeking Alpha | ||
18.02. | Arcus Biosciences advances cancer drug casdatifan post Gilead deal expiry | 5 | Investing.com | ||
18.02. | Arcus Biosciences treibt Krebsmedikament Casdatifan nach Auslaufen des Gilead-Deals voran | 16 | Investing.com Deutsch | ||
18.02. | Arcus Biosciences sets $11/share for $150M stock offering | 1 | Investing.com | ||
18.02. | Arcus Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
06.02. | Arcus Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
21.01. | Arcus Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
04.12.24 | Arcus Biosciences' Chefbuchhalter verkauft Aktien im Wert von 3.079 US-Dollar | 6 | Investing.com Deutsch | ||
07.11.24 | Arcus Biosciences GAAP EPS of -$1.00 beats by $0.04, revenue of $48M beats by $9.05M | 2 | Seeking Alpha | ||
06.11.24 | Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update | 155 | Business Wire | HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies... ► Artikel lesen | |
06.11.24 | Arcus Biosciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
06.11.24 | Arcus Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
06.11.24 | Expert Outlook: Arcus Biosciences Through The Eyes Of 8 Analysts | 1 | Benzinga.com | ||
25.10.24 | Arcus Biosciences (NYSE:RCUS) Trading Down 5.3% - Should You Sell? | 3 | MarketBeat |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 84,90 | +2,97 % | BioNTech-Aktie: Sie haben keine Ahnung! | News von Trading-Treff.de Für BioNTech ist aktuell der Trend nach unten gerichtet. Auch am Freitag ging es um über 1,2 % abwärts. Die Aktie war in den vergangenen Wochen schon der Katastrophe nahe.... ► Artikel lesen | |
CUREVAC | 2,544 | -1,47 % | Aktien New York Ausblick: Leichte Kursverluste erwartet | NEW YORK (dpa-AFX) - Die US-Aktienmärkte dürften am Freitag an ihre moderaten Vortagesverluste anknüpfen. Im Fokus steht weiterhin der drohende globale Handelskrieg. Die von US-Präsident Donald Trump... ► Artikel lesen | |
STRYKER | 344,30 | 0,00 % | Dividendenbekanntmachungen (31.03.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIA REALTY TRUST US0042391096 0,2 USD 0,1847 EUR ACADIAN TIMBER CORP CA0042721005 0,29 CAD 0,187 EUR ADVANCED FLOWER CAPITAL... ► Artikel lesen | |
INFLARX | 1,007 | +3,98 % | InflaRx Aktie: Marktanteile stark erweitert! | Das Biopharma-Unternehmen sichert sich europäische Zulassung für sein COVID-ARDS-Medikament und erreicht wichtige Meilensteine in klinischen Studien bei weiteren Indikationen. Die InflaRx-Aktie notiert... ► Artikel lesen | |
NEUROCRINE BIOSCIENCES | 99,72 | -2,00 % | Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential | ||
VAXART | 0,369 | -5,04 % | Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced that on March 24, 2025, the independent members of the Board... ► Artikel lesen | |
HALOZYME THERAPEUTICS | 57,36 | -2,78 % | Halozyme: Bristol Myers Squibb Secures CHMP's Positive Opinion For New Cancer Drug Delivery Method | NEW YORK CITY (dpa-AFX) - Halozyme Therapeutics, Inc. (HALO), Monday announced that Bristol Myers Squibb (BMY) received a positive opinion from the Committee for Medicinal Products for Human... ► Artikel lesen | |
IMMATICS | 3,828 | -8,11 % | Immatics Announces Full Year 2024 Financial Results and Business Update | Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient randomized and enrollment continues as plannedACTengine® IMA203... ► Artikel lesen | |
XOMA ROYALTY | 18,400 | -1,08 % | The Analyst Verdict: XOMA Royalty In The Eyes Of 4 Experts | ||
MANNKIND | 4,525 | -2,81 % | MannKind Corp. Q4 Earnings Summary | WASHINGTON (dpa-AFX) - Below are the earnings highlights for MannKind Corp. (MNKD):Earnings: $7.42 million in Q4 vs. $1.40 million in the same period last year.
EPS: $0.03 in Q4 vs. $0.00... ► Artikel lesen | |
BEIGENE LTD ADR | 248,00 | -1,59 % | BeiGene, Ltd.: BeiGene erhält positive CHMP-Stellungnahme für TEVIMBRA als Erstlinienbehandlung bei kleinzelligem Lungenkrebs im extensiven Stadium | Positive Stellungnahme für die Erstlinienbehandlung von kleinzelligem Lungenkrebs im extensiven Stadium auf der Grundlage der Ergebnisse der RATIONALE-312-Studie, die einen statistisch signifikanten... ► Artikel lesen | |
AC IMMUNE | 1,670 | -3,69 % | AC Immune SA: AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD 2025 | ||
ESPERION | 1,290 | -3,44 % | Esperion appoints Robert Hoffman to board of directors | ||
RECORDATI | 52,15 | -0,76 % | Recordati: RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS | RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4%PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS
Consolidated net revenue... ► Artikel lesen | |
ARDELYX | 4,458 | -1,72 % | Ardelyx, Inc.: Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH (tenapanor) at the National Kidney Foundation Spring Clinical Meetings |